Literature DB >> 23072726

Tyrosine metabolism during interferon-alpha administration: association with fatigue and CSF dopamine concentrations.

Jennifer C Felger1, Li Li, Paul J Marvar, Bobbi J Woolwine, David G Harrison, Charles L Raison, Andrew H Miller.   

Abstract

Chronic exposure to interferon (IFN)-alpha, an innate immune cytokine, produces high rates of behavioral disturbances, including depression and fatigue. These effects may be mediated by the actions of IFN-alpha on dopamine (DA) metabolism in the basal ganglia. Diminished conversion of phenylalanine (Phen) to tyrosine (Tyr), the primary amino acid precursor of DA, has been associated with inflammation, and may reflect decreased activity of the enzyme phenylalanine-hydroxylase (PAH). This study investigated the peripheral Phen/Tyr ratio in relation to cerebrospinal fluid (CSF) concentrations of DA and its metabolites in subjects treated with IFN-alpha plus ribavirin for hepatitis C and controls awaiting IFN-alpha therapy. Plasma Phen/Tyr ratios were significantly increased in IFN-alpha-treated subjects (n=25) compared to controls (n=9), and were negatively correlated with CSF DA (r=-0.59, df=15, p<0.05) and its metabolite, homovanillic acid (r=-0.67, df=15, p<0.01), and positively correlated with fatigue (r=0.44, df=23, p<.05) in IFN-alpha-treated patients but not controls. Given the role of tetrahydrobiopterin (BH4) in the PAH conversion of Phen to Tyr, CSF concentrations of BH4 and its inactive oxidized form, dihydrobiopterin (BH2), were examined along with CSF interleukin (IL)-6 in a subset of patients. BH2 concentrations were significantly increased in IFN-alpha-treated patients (n=12) compared to controls (n=7), and decreased CSF BH4 concentrations correlated with increased CSF IL-6 (r=-0.57, df=12, p<0.05). These results indicate that IFN-alpha is associated with decreased peripheral conversion of Phen to Tyr, which in turn is associated with reduced DA in the brain as well as fatigue. These alterations may be related to oxidation of BH4 secondary to IFN-alpha-induced activation of a CNS inflammatory response.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23072726      PMCID: PMC3578984          DOI: 10.1016/j.bbi.2012.10.010

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  76 in total

1.  Residual symptoms in depressed patients who respond acutely to fluoxetine.

Authors:  A A Nierenberg; B R Keefe; V C Leslie; J E Alpert; J A Pava; J J Worthington; J F Rosenbaum; M Fava
Journal:  J Clin Psychiatry       Date:  1999-04       Impact factor: 4.384

2.  Chronic low-grade inflammation in elderly persons is associated with altered tryptophan and tyrosine metabolism: role in neuropsychiatric symptoms.

Authors:  Lucile Capuron; Sebastian Schroecksnadel; Catherine Féart; Agnès Aubert; Denise Higueret; Pascale Barberger-Gateau; Sophie Layé; Dietmar Fuchs
Journal:  Biol Psychiatry       Date:  2011-01-31       Impact factor: 13.382

3.  Norman Cousins Lecture. Mechanisms of cytokine-induced behavioral changes: psychoneuroimmunology at the translational interface.

Authors:  Andrew H Miller
Journal:  Brain Behav Immun       Date:  2008-09-03       Impact factor: 7.217

4.  Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression.

Authors:  Charles L Raison; Andrey S Borisov; Matthias Majer; Daniel F Drake; Giuseppe Pagnoni; Bobbi J Woolwine; Gerald J Vogt; Breanne Massung; Andrew H Miller
Journal:  Biol Psychiatry       Date:  2008-09-18       Impact factor: 13.382

5.  Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.

Authors:  B Stankoff; E Waubant; C Confavreux; G Edan; M Debouverie; L Rumbach; T Moreau; J Pelletier; C Lubetzki; M Clanet
Journal:  Neurology       Date:  2005-04-12       Impact factor: 9.910

6.  Basal ganglia hypermetabolism and symptoms of fatigue during interferon-alpha therapy.

Authors:  Lucile Capuron; Giuseppe Pagnoni; Marina F Demetrashvili; David H Lawson; Fiona B Fornwalt; Bobbi Woolwine; Gregory S Berns; Charles B Nemeroff; Andrew H Miller
Journal:  Neuropsychopharmacology       Date:  2007-02-28       Impact factor: 7.853

7.  Mechanism of systemically injected interferon-alpha impeding monoamine biosynthesis in rats: role of nitric oxide as a signal crossing the blood-brain barrier.

Authors:  Tomitsune Kitagami; Kiyofumi Yamada; Hideki Miura; Ryo Hashimoto; Toshitaka Nabeshima; Tatsurou Ohta
Journal:  Brain Res       Date:  2003-07-18       Impact factor: 3.252

8.  Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 1: predictors of clinical response in fluoxetine-resistant depression.

Authors:  George I Papakostas; Timothy Petersen; David Mischoulon; Julie L Ryan; Andrew A Nierenberg; Teodoro Bottiglieri; Jerrold F Rosenbaum; Jonathan E Alpert; Maurizio Fava
Journal:  J Clin Psychiatry       Date:  2004-08       Impact factor: 4.384

9.  Cytokine-induced depression during IFN-alpha treatment: the role of IL-6 and sleep quality.

Authors:  Aric A Prather; Mordechai Rabinovitz; Bruce G Pollock; Francis E Lotrich
Journal:  Brain Behav Immun       Date:  2009-07-15       Impact factor: 7.217

10.  Recovery after L-DOPA treatment in peginterferon and ribavirin induced parkinsonism.

Authors:  A Bersano; A Aghemo; M G Rumi; E Ballabio; L Candelise; M Colombo
Journal:  Eur J Intern Med       Date:  2007-11-28       Impact factor: 4.487

View more
  64 in total

Review 1.  Nutritional modulation of the intestinal microbiota; future opportunities for the prevention and treatment of neuroimmune and neuroinflammatory disease.

Authors:  Vincent C Lombardi; Kenny L De Meirleir; Krishnamurthy Subramanian; Sam M Nourani; Ruben K Dagda; Shannon L Delaney; András Palotás
Journal:  J Nutr Biochem       Date:  2018-04-19       Impact factor: 6.048

2.  Chronic interferon-α decreases dopamine 2 receptor binding and striatal dopamine release in association with anhedonia-like behavior in nonhuman primates.

Authors:  Jennifer C Felger; Jiyoung Mun; Heather L Kimmel; Jonathon A Nye; Daniel F Drake; Carla R Hernandez; Amanda A Freeman; David B Rye; Mark M Goodman; Leonard L Howell; Andrew H Miller
Journal:  Neuropsychopharmacology       Date:  2013-05-09       Impact factor: 7.853

Review 3.  Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications.

Authors:  J C Felger; F E Lotrich
Journal:  Neuroscience       Date:  2013-05-03       Impact factor: 3.590

Review 4.  Role of Adiposity-Driven Inflammation in Depressive Morbidity.

Authors:  Lucile Capuron; Julie Lasselin; Nathalie Castanon
Journal:  Neuropsychopharmacology       Date:  2016-07-11       Impact factor: 7.853

Review 5.  Can't or Won't? Immunometabolic Constraints on Dopaminergic Drive.

Authors:  Michael T Treadway; Jessica A Cooper; Andrew H Miller
Journal:  Trends Cogn Sci       Date:  2019-04-02       Impact factor: 20.229

Review 6.  Inflammatory cytokine-associated depression.

Authors:  Francis E Lotrich
Journal:  Brain Res       Date:  2014-07-05       Impact factor: 3.252

Review 7.  Role of interferon alpha in endothelial dysfunction: insights into endothelial nitric oxide synthase-related mechanisms.

Authors:  Joy N Jones Buie; Jim C Oates
Journal:  Am J Med Sci       Date:  2014-08       Impact factor: 2.378

Review 8.  Therapeutic Implications of Brain-Immune Interactions: Treatment in Translation.

Authors:  Andrew H Miller; Ebrahim Haroon; Jennifer C Felger
Journal:  Neuropsychopharmacology       Date:  2016-08-24       Impact factor: 7.853

Review 9.  Inflammation Effects on Motivation and Motor Activity: Role of Dopamine.

Authors:  Jennifer C Felger; Michael T Treadway
Journal:  Neuropsychopharmacology       Date:  2016-08-02       Impact factor: 7.853

10.  Effort-related motivational effects of the pro-inflammatory cytokine interleukin-6: pharmacological and neurochemical characterization.

Authors:  Samantha E Yohn; Yumna Arif; Allison Haley; Guiseppe Tripodi; Younis Baqi; Christa E Müller; Noemi San Miguel; Mercè Correa; John D Salamone
Journal:  Psychopharmacology (Berl)       Date:  2016-08-06       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.